King's College London

Research portal

Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets

Research output: Contribution to journalArticle

Standard

Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets. / Lincoln, Louise; Fisher, Ria; Jackson, Michael J.; Jenner, Peter; Neumeyer, John; Sromek, Anna W.; Lees, Andrew J.; Rose, Sarah.

In: Movement disorders : official journal of the Movement Disorder Society, Vol. 31, No. 9, 02.05.2016, p. 1381-1388.

Research output: Contribution to journalArticle

Harvard

Lincoln, L, Fisher, R, Jackson, MJ, Jenner, P, Neumeyer, J, Sromek, AW, Lees, AJ & Rose, S 2016, 'Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets', Movement disorders : official journal of the Movement Disorder Society, vol. 31, no. 9, pp. 1381-1388. https://doi.org/10.1002/mds.26626

APA

Lincoln, L., Fisher, R., Jackson, M. J., Jenner, P., Neumeyer, J., Sromek, A. W., ... Rose, S. (2016). Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets. Movement disorders : official journal of the Movement Disorder Society, 31(9), 1381-1388. https://doi.org/10.1002/mds.26626

Vancouver

Lincoln L, Fisher R, Jackson MJ, Jenner P, Neumeyer J, Sromek AW et al. Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets. Movement disorders : official journal of the Movement Disorder Society. 2016 May 2;31(9):1381-1388. https://doi.org/10.1002/mds.26626

Author

Lincoln, Louise ; Fisher, Ria ; Jackson, Michael J. ; Jenner, Peter ; Neumeyer, John ; Sromek, Anna W. ; Lees, Andrew J. ; Rose, Sarah. / Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets. In: Movement disorders : official journal of the Movement Disorder Society. 2016 ; Vol. 31, No. 9. pp. 1381-1388.

Bibtex Download

@article{97a2a895ea3e4f659e9118e306934a6b,
title = "Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets",
abstract = "Background: The D1/D2 dopamine agonist apomorphine has poor oral bioavailability, necessitating subcutaneous administration in the treatment of Parkinson's disease (PD). Acute subcutaneous injection is used as rescue therapy from {"}off{"} periods, whereas continuous subcutaneous infusion is used to increase {"}on{"} periods and to reduce dyskinesia when oral treatment fails. An orally active derivative of apomorphine would avoid the need for parenteral administration. We now describe the effects of the orally active compound R-(-)-11-O-valeryl-N-n-propylnoraporphine (11-OH-NPa valerate) on reversal of motor disability and expression of dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated, l-dopa-primed dyskinetic common marmosets. Methods: Locomotor activity, motor disability, and dyskinesia were assessed in MPTP-treated marmosets following the administration of apomorphine (0.075 mg/kg, subcutaneous and 0.28 to 1.12 mg/kg, oral) and 11-OH-NPa valerate (0.19, 0.38, and 0.75mg/kg, oral). Results: Subcutaneous administration of apomorphine (0.075 mg/kg) produced a short-lasting reversal of motor disability and the expression of established dyskinesia, but when administered orally (0.28-1.12 mg/kg) it had no effect. In contrast, oral treatment with 11-OH-NPa valerate (0.19 and 0.75 mg/kg) induced a dose-related reversal of motor disability and increased locomotor activity with only mild to moderate dyskinesia. Only at the highest dose (0.75 mg/kg) was marked dyskinesia seen accompanying an extended period of motor disability reversal and increased locomotor activity.Conclusion: Oral administration of 11-OH-NPa valerate produced a rapid reversal of motor disability and, at effective dose levels, had a limited propensity to induce dyskinesia. 11-OH-NPa valerate is the first orally active derivative of apomorphine with potential for use in PD.",
keywords = "11-OH-NPa valerate, Apomorphine, Marmosets, MPTP, Parkinson's disease, R-(-)-11-O-valeryl-N-n-propylnoraporphine",
author = "Louise Lincoln and Ria Fisher and Jackson, {Michael J.} and Peter Jenner and John Neumeyer and Sromek, {Anna W.} and Lees, {Andrew J.} and Sarah Rose",
year = "2016",
month = "5",
day = "2",
doi = "10.1002/mds.26626",
language = "English",
volume = "31",
pages = "1381--1388",
journal = "Movement disorders : official journal of the Movement Disorder Society",
issn = "0885-3185",
number = "9",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets

AU - Lincoln, Louise

AU - Fisher, Ria

AU - Jackson, Michael J.

AU - Jenner, Peter

AU - Neumeyer, John

AU - Sromek, Anna W.

AU - Lees, Andrew J.

AU - Rose, Sarah

PY - 2016/5/2

Y1 - 2016/5/2

N2 - Background: The D1/D2 dopamine agonist apomorphine has poor oral bioavailability, necessitating subcutaneous administration in the treatment of Parkinson's disease (PD). Acute subcutaneous injection is used as rescue therapy from "off" periods, whereas continuous subcutaneous infusion is used to increase "on" periods and to reduce dyskinesia when oral treatment fails. An orally active derivative of apomorphine would avoid the need for parenteral administration. We now describe the effects of the orally active compound R-(-)-11-O-valeryl-N-n-propylnoraporphine (11-OH-NPa valerate) on reversal of motor disability and expression of dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated, l-dopa-primed dyskinetic common marmosets. Methods: Locomotor activity, motor disability, and dyskinesia were assessed in MPTP-treated marmosets following the administration of apomorphine (0.075 mg/kg, subcutaneous and 0.28 to 1.12 mg/kg, oral) and 11-OH-NPa valerate (0.19, 0.38, and 0.75mg/kg, oral). Results: Subcutaneous administration of apomorphine (0.075 mg/kg) produced a short-lasting reversal of motor disability and the expression of established dyskinesia, but when administered orally (0.28-1.12 mg/kg) it had no effect. In contrast, oral treatment with 11-OH-NPa valerate (0.19 and 0.75 mg/kg) induced a dose-related reversal of motor disability and increased locomotor activity with only mild to moderate dyskinesia. Only at the highest dose (0.75 mg/kg) was marked dyskinesia seen accompanying an extended period of motor disability reversal and increased locomotor activity.Conclusion: Oral administration of 11-OH-NPa valerate produced a rapid reversal of motor disability and, at effective dose levels, had a limited propensity to induce dyskinesia. 11-OH-NPa valerate is the first orally active derivative of apomorphine with potential for use in PD.

AB - Background: The D1/D2 dopamine agonist apomorphine has poor oral bioavailability, necessitating subcutaneous administration in the treatment of Parkinson's disease (PD). Acute subcutaneous injection is used as rescue therapy from "off" periods, whereas continuous subcutaneous infusion is used to increase "on" periods and to reduce dyskinesia when oral treatment fails. An orally active derivative of apomorphine would avoid the need for parenteral administration. We now describe the effects of the orally active compound R-(-)-11-O-valeryl-N-n-propylnoraporphine (11-OH-NPa valerate) on reversal of motor disability and expression of dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated, l-dopa-primed dyskinetic common marmosets. Methods: Locomotor activity, motor disability, and dyskinesia were assessed in MPTP-treated marmosets following the administration of apomorphine (0.075 mg/kg, subcutaneous and 0.28 to 1.12 mg/kg, oral) and 11-OH-NPa valerate (0.19, 0.38, and 0.75mg/kg, oral). Results: Subcutaneous administration of apomorphine (0.075 mg/kg) produced a short-lasting reversal of motor disability and the expression of established dyskinesia, but when administered orally (0.28-1.12 mg/kg) it had no effect. In contrast, oral treatment with 11-OH-NPa valerate (0.19 and 0.75 mg/kg) induced a dose-related reversal of motor disability and increased locomotor activity with only mild to moderate dyskinesia. Only at the highest dose (0.75 mg/kg) was marked dyskinesia seen accompanying an extended period of motor disability reversal and increased locomotor activity.Conclusion: Oral administration of 11-OH-NPa valerate produced a rapid reversal of motor disability and, at effective dose levels, had a limited propensity to induce dyskinesia. 11-OH-NPa valerate is the first orally active derivative of apomorphine with potential for use in PD.

KW - 11-OH-NPa valerate

KW - Apomorphine

KW - Marmosets

KW - MPTP

KW - Parkinson's disease

KW - R-(-)-11-O-valeryl-N-n-propylnoraporphine

UR - http://www.scopus.com/inward/record.url?scp=84964703706&partnerID=8YFLogxK

U2 - 10.1002/mds.26626

DO - 10.1002/mds.26626

M3 - Article

VL - 31

SP - 1381

EP - 1388

JO - Movement disorders : official journal of the Movement Disorder Society

JF - Movement disorders : official journal of the Movement Disorder Society

SN - 0885-3185

IS - 9

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454